The Problem: We Don’t Really Know! The problem with estimating the total cost burden of the autoimmune disease (AIID) epidemic is that we really don’t know! A May 2022 NIH report validates our long-held belief that missing and inconsistent data for autoimmune diseases (AIIDs) are at the root of the
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
We’ve compiled some incidence, prevalence and growth estimates for selected autoimmune diseases (AIIDs) as a follow up to our previous post. In that post, we surveyed the sorry state of US national autoimmune incidence & prevalence data. Summary: Per the May 2022 NIH Report: Enhancing Autoimmune Research the US has
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.
Autoimmune disease is an umbrella term for the numerous diseases that affect the immune system. The overlap of symptoms makes them difficult to diagnose and understand. Continue reading to help bring the invisible epidemic of autoimmune disease into the limelight.
How Big Data is Changing Current Research Methodology: Cancer Cancer is the second leading cause of death in the United States. Current treatments are ineffective with over 75% of patients not responding to treatments, despite the $50 billion pharmaceutical companies spend in research and development every year. In addition, patients
Genomics is making headlines in both academia and the celebrity world. When genetic tests revealed that Angelina Jolie was predisposed to breast cancer, intense media cover ensued. Since then, genetic testing and genomics have been propelled to the front of many more minds. In this new data field, companies are
Salivary diagnostics may be a cheaper, faster and better way to diagnose certain diseases. Already effective in oral cancer and Sjogren’s syndrome, researchers are looking to expand the potential of using saliva. Blood tests and biopsies are invasive, expensive, and time-consuming to collect and
Part Three: Election Day special: Regulatory Obstacles (continued from Part Two) By Ellen Martin Here is a 352-page description of US healthcare regulation as of 2006: Robert I. Field’s Health Care Regulation in America: Complexity, Confrontation, and Compromise. It is always mind boggling to hear so many people toss throwaway lines about